. Author manuscript; available in PMC: 2019 Jan 30.

Published in final edited form as: Prostate Cancer Prostatic Dis. 2012 Mar 6;15(3):289–295. doi: 10.1038/pcan.2012.7

Table 2.

Long-term clinical outcomes of patients

	S-IL-2	M-IL-2	Placebo	P-value
Median follow-up (range)	98 m (16 – 115)	76 m (61 – 86)	79 m (56 – 86)
Actuarial 5-year PSA failure-free probability	78%	82%	86%	0.58
PSA failure^a by NCCN risk group
Low	0% (0/2)	0% (0/3)	0% (0/1)	1.00
Intermediate	20% (1/5)	0% (0/5)	0% (0/2)
High	55% (6/11)	40% (4/10)	25% (1/4)
Actuarial 5-year OS probability	94%	100%	NA	0.76
Actuarial 5-year PCSS probability	94%	100%	NA	0.55

Abbreviations: IL, interleukin; m, months; M-IL-2, metronomic dose IL-2; NCCN, National Comprehensive Cancer Network; NA, not applicable; OS, overall survival; PCSS, prostate cancer-specific survival; S-IL-2, standard dose IL-2.

Phoenix definition.